New pill shows promise for tough eczema in small study

NCT ID NCT06585202

Completed Disease control Sponsor: Aclaris Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental oral drug called ATI-2138 in 14 adults with moderate to severe atopic dermatitis (eczema). Participants took the pill twice daily for 12 weeks. Researchers tracked safety, side effects, and skin improvement using standard eczema scores. The goal was to see if the drug is safe and might reduce skin redness, itching, and rash.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ATI-2138 oral tablets
What this could lead to: If successful, this could point toward a new oral treatment option for moderate to severe atopic dermatitis, potentially reducing skin inflammation and itching.
What could go wrong: This is a small, early-phase study with only 14 participants and no placebo group, so results may not apply broadly. Side effects are possible, and the drug may not prove effective in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema Skin Diseases, Eczematous skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Aclaris Investigational Site

Birmingham, Alabama, 35244, United States
Aclaris Investigational Site

Encino, California, 91436, United States
Aclaris Investigational Site

San Diego, California, 92123, United States
Aclaris Investigational Site

Plainfield, Indiana, 46168, United States
Aclaris Investigational Site

Austin, Texas, 78759, United States
Aclaris Investigational Site

San Antonio, Texas, 78213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.